Dynamic Technology Lab Private Ltd Buys 5,918 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Dynamic Technology Lab Private Ltd grew its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 213.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,690 shares of the company's stock after purchasing an additional 5,918 shares during the quarter. Dynamic Technology Lab Private Ltd's holdings in Prestige Consumer Healthcare were worth $679,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in PBH. Kestra Investment Management LLC bought a new stake in Prestige Consumer Healthcare in the fourth quarter valued at $27,000. CIBC Private Wealth Group LLC lifted its position in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after purchasing an additional 152 shares during the last quarter. Headlands Technologies LLC acquired a new position in Prestige Consumer Healthcare during the 4th quarter valued at about $40,000. GAMMA Investing LLC grew its position in Prestige Consumer Healthcare by 18.9% in the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock worth $108,000 after purchasing an additional 220 shares during the last quarter. Finally, Huntington National Bank increased its stake in shares of Prestige Consumer Healthcare by 133.2% in the fourth quarter. Huntington National Bank now owns 1,481 shares of the company's stock valued at $116,000 after purchasing an additional 846 shares during the period. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH traded up $1.46 during midday trading on Friday, reaching $82.17. The company's stock had a trading volume of 357,520 shares, compared to its average volume of 284,137. The company has a market cap of $4.07 billion, a price-to-earnings ratio of 19.24, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a 50 day moving average price of $84.56 and a 200 day moving average price of $79.89. Prestige Consumer Healthcare Inc. has a one year low of $62.35 and a one year high of $90.04.

Remove Ads

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at $1,544,130. This represents a 8.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PBH shares. Oppenheimer increased their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. Raymond James raised Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. StockNews.com downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Tuesday, April 8th. Canaccord Genuity Group increased their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Finally, DA Davidson boosted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of "Hold" and an average target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.